Nivolumab instills hope in a hopeless situation in advanced nonsmall cell lung cancer with poor performance status

Given the favorable toxicity profile and unique mechanism of action, it is worth exploring nivolumab in the treatment of advanced nonsmall cell lung cancer with poor PS patients, who are otherwise offered only best supportive care. [3],[4] Immunotherapy is a potential modality of anticancer therapy...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Indian journal of cancer 2017-01, Vol.54 (1), p.55
Hauptverfasser:	Chandrakanth, M V, Noronha, V, Joshi, A, Patil, V, Mahajan, A, Prabhash, K
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - therapeutic use Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Cancer therapies Carcinoma, Non-Small-Cell Lung - immunology Carcinoma, Non-Small-Cell Lung - therapy Care and treatment Chemotherapy Diagnosis Disease Progression Drug therapy Drug-Related Side Effects and Adverse Reactions Exanthema - etiology Humans Immunotherapy - methods Lung - diagnostic imaging Lung - drug effects Lung - pathology Lung cancer Lung Neoplasms - immunology Lung Neoplasms - therapy Male Medical prognosis Metastasis Middle Aged Monoclonal antibodies Mutation Neoplasm Staging Nivolumab Non-small cell lung cancer Oncology Patient outcomes Patients Programmed Cell Death 1 Receptor - immunology Remission Induction Targeted cancer therapy Vertebrae
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!